Blacklisted
Medicines Food Cosmetics AYUSH
Check a batch

State licensing authorities, CDSCO, Ministry of AYUSH and courts

AYUSH medicines: orders, suspensions and lab findings (2026)

Last checked 10 October 2026

15 entries. Status uses the authority's own words: a licence suspended is suspended, a batch that failed a state lab test is a failed test, a product seized under the advertising law is a seizure, and a stayed order is stayed. None of these is a national ban unless a gazette notification says so.

AllIngredient and claim rulesBrandsFact-checks

All entries

No action
Himalaya Wellness: Not banned; no action on record

Himalaya Wellness (Liv.52): what is on record

No action is on record against Himalaya Wellness or Liv.52: no ban, recall, failed lab test or notice appears in the Maharashtra FDA table of 9 Oct 2026, the CDSCO Ayush page or the US FDA import alerts for India.

  • Status: Not banned; no action on record
  • Who decided: No regulator action on record
  • Reference: Sources checked: Maharashtra FDA NSQ table (9 Oct 2026); CDSCO Ayush division page; US FDA import alerts, India list (9 Oct 2026)
  • What to do: No record is not a certificate
Read the full entry
NSQ
Ayurvedic medicines NSQ: Declared not of standard quality: Maharashtra FDA table (as of 9 Oct 2026)

Ayurvedic medicines that failed state lab tests: Maharashtra FDA table

Maharashtra FDA's table, as of 9 Oct 2026, lists ten Inducare Pharma products and Divya Pharmacy's Arjuna Kwath as not of standard quality for fungus, microbial limits or description; each row is a finding on a tested sample, not a ban.

  • Status: Declared not of standard quality: Maharashtra FDA table (as of 9 Oct 2026)
  • Who decided: Maharashtra Food and Drug Administration
  • Latest step: 9 Oct 2026: Maharashtra FDA's NSQ table, updated 9 Oct 2026, lists the Inducare products and Divya Arjuna Kwath
  • Reference: Maharashtra FDA NSQ alerts table, 190 rows as of 9 Oct 2026, about 20 for ayurvedic, siddha and unani products
  • What to do: A failed sample is not a ban
Read the full entry
Spurious
Ayurvedic medicine with allopathic drug: Found to contain undeclared drugs: Maharashtra FDA NSQ table (as of 9 Oct 2026)

Ayurvedic-labelled products found to contain allopathic drugs: Maharashtra FDA rows

Maharashtra FDA's table, as of 9 Oct 2026, lists four products sold as ayurvedic that contained undeclared drugs: paracetamol and diclofenac, metformin, famotidine, and mercury. Each is one finding on one product, not a finding about a licensed brand.

  • Status: Found to contain undeclared drugs: Maharashtra FDA NSQ table (as of 9 Oct 2026)
  • Who decided: Maharashtra Food and Drug Administration
  • Latest step: 9 Oct 2026: Maharashtra FDA's NSQ table (as updated 9 Oct 2026) lists products sold as ayurvedic that were found to contain paracetamol and diclofenac, metformin or famotidine, and an unlabelled product with mercury
  • Reference: Maharashtra FDA NSQ alerts table, as read on 9 Oct 2026
  • What to do: Do not link these to a licensed brand
Read the full entry
Notice
Maharashtra FDA ayurvedic drive: 434 units inspected, 135 notices, 10 licences cancelled (Aug 2026)

Maharashtra FDA's ayurvedic manufacturers drive: 434 units, 10 licences cancelled (Aug 2026)

By Aug 2026 Maharashtra FDA had inspected 434 ayurvedic manufacturing units, issued 135 show-cause notices and permanently cancelled 10 licences for failures against Schedule T, the good manufacturing practice requirements.

  • Status: 434 units inspected, 135 notices, 10 licences cancelled (Aug 2026)
  • Who decided: Maharashtra Food and Drug Administration
  • Latest step: 12 Aug 2026: Maharashtra FDA's drive reported: 434 ayurvedic units inspected, 135 show-cause notices, 10 licences permanently cancelled (Open magazine)
  • Reference: Reported in Open magazine, Aug 2026; the list of units and orders is not published
  • What to do: A notice is a first step
Read the full entry
Licence suspended
Inducare Pharma: Licence cancelled (8 Aug 2026)

Maharashtra FDA cancels Inducare Pharma's licence (Aug 2026)

Maharashtra FDA cancelled the manufacturing licence of Inducare Pharma Pvt Ltd, Jejuri, on 8 Aug 2026 after fungus, insects and larvae were found in six of its products; ten Inducare products also appear in the FDA's table of failed lab tests.

  • Status: Licence cancelled (8 Aug 2026)
  • Who decided: Maharashtra Food and Drug Administration
  • Latest step: 8 Aug 2026: Maharashtra FDA cancels the licence of Inducare Pharma Pvt Ltd, Jejuri, after fungus, insects and larvae were found in six products
  • Reference: Licence cancellation of 8 Aug 2026 (reported); Maharashtra FDA NSQ alerts table, as of 9 Oct 2026
  • What to do: This is a firm-level action
Read the full entry
Banned
Kerala ayurvedic medicines banned: Sale banned in Kerala, 6 batches (Jul 2026)

Kerala bans sale of six substandard ayurvedic and siddha batches (Jul 2026)

In Jul 2026 Kerala's Deputy Drugs Controller (Ayurveda) banned the sale and distribution in Kerala of six batches found substandard: Kasakalpa, Viswasasudharana, Swasakalpa, Swasa Spatikaamrutha, Vizzle (a siddha product) and Pain Niwaran Churna.

  • Status: Sale banned in Kerala, 6 batches (Jul 2026)
  • Who decided: Deputy Drugs Controller (Ayurveda), Kerala
  • Latest step: 13 Jul 2026: Kerala Drugs Control Department bans sale and distribution of six batches; traders and pharmacies told to return stock (reported 13 Jul 2026)
  • Reference: Kerala Drugs Control Department order, Jul 2026 (reported; the official site could not be read)
  • What to do: It is a batch order for one state
Read the full entry
Halted
Phenolphthalein homoeopathic: DCGI circular: stop manufacture and sale (6 Jul 2026)

DCGI circular on homoeopathic medicines containing phenolphthalein (Jul 2026)

On 6 Jul 2026 the Drugs Controller General of India told state drug controllers to stop the manufacture and sale of combinations containing phenolphthalein sold as homoeopathic medicines, because they do not meet the definition in Rule 2(dd) of the Drugs and Cosmetics Rules.

  • Status: DCGI circular: stop manufacture and sale (6 Jul 2026)
  • Who decided: Drugs Controller General of India (CDSCO)
  • Latest step: 6 Jul 2026: DCGI circular: states told to stop manufacture and sale of homoeopathic combinations containing phenolphthalein
  • Reference: DCGI circular dated 6 Jul 2026, 'Manufacturing and marketing of Homoeopathic medicines containing Phenolphthalein'
  • What to do: It is not a ban on homoeopathy
Read the full entry
Notice
Divya Pharmacy seizure Maharashtra: DMR Act seizure; before the Bombay High Court (Jun 2026)

Maharashtra FDA seizes Divya Pharmacy products over cure claims (Jun 2026)

In Jun 2026 Maharashtra FDA seized about Rs 51 lakh of Divya Pharmacy products for 'miraculous cure' claims under the Drugs and Magic Remedies Act; Patanjali went to the Bombay High Court and the state said it would take no coercive action for the time being.

  • Status: DMR Act seizure; before the Bombay High Court (Jun 2026)
  • Who decided: Maharashtra Food and Drug Administration
  • Latest step: 13 Jun 2026: Maharashtra FDA's statewide raids and the seizure of about Rs 51 lakh of Divya Pharmacy products under the DMR Act reported (ThePrint); Patanjali moves the Bombay High Court
  • Reference: Drugs and Magic Remedies (Objectionable Advertisements) Act 1954; Bombay High Court petition by Patanjali (reported); no order published
  • What to do: A seizure is not a ban
Read the full entry
Notice
US FDA import alert ayurvedic: US border alerts; not an Indian action (2021 to 2026)

US FDA import alerts and warnings on Indian ayurvedic products (2021 to 2026)

The US FDA's heavy-metals import alert 99-42 lists Baidyanath bati products (1 Apr 2021), Falcon System (8 May 2025) and Kerala Ayurveda's Guluchyadi Kwath (7 Apr 2026), and the FDA warned about Rheumacare on 2 Dec 2025; these are US border measures, not Indian actions.

  • Status: US border alerts; not an Indian action (2021 to 2026)
  • Who decided: US Food and Drug Administration (not an Indian regulator)
  • Latest step: 7 Apr 2026: US FDA lists Kerala Ayurveda Ltd, Guluchyadi Kwath, for lead on Import Alert 99-42
  • Reference: US FDA Import Alert 99-42 (updated 22 Sep 2026); FDA warning of 2 Dec 2025
  • What to do: A US border matter
Read the full entry
Notice
Ayush Suraksha: Reporting portal live since 30 May 2025

Ayush Suraksha portal: how to report a misleading ayurvedic advertisement

The Ayush Suraksha portal, launched on 30 May 2025, takes public reports of misleading AYUSH advertisements and adverse reactions; it reported 35 misleading ads and 181 complaints resolved by Dec 2025, but publishes no list of ads, products or actions.

  • Status: Reporting portal live since 30 May 2025
  • Who decided: Ministry of AYUSH: PvPI-ASU&H, National Pharmacovigilance Coordination Centre at AIIA
  • Latest step: 2 Dec 2025: PIB reports 35 misleading ads reported by the public and 181 complaints resolved
  • Reference: PIB release of 2 Dec 2025; PIB release of 3 Dec 2024; Lok Sabha reply reported by Outlook (2026)
  • What to do: How to report
Read the full entry
Not banned
Dabur: Not banned; no Indian AYUSH action on record

Dabur's ayurvedic products: what is on record

No Indian AYUSH action against Dabur is on record: Dabur Chyawanprash is not banned and Dabur was the plaintiff in the Delhi High Court case of 6 Nov 2025, while Hajmola and Fem bleach appear on the US FDA's unapproved-drug import alert (2024), a US border matter.

  • Status: Not banned; no Indian AYUSH action on record
  • Who decided: No Indian regulator action on record
  • Latest step: 6 Nov 2025: Delhi High Court grants Dabur interim relief and restrains Patanjali from calling all other chyawanprash 'dhoka'
  • Reference: Delhi High Court, Dabur India v Patanjali Ayurved, 6 Nov 2025; US FDA Import Alert 66-41 (India list updated 9 Oct 2026)
  • What to do: The US entries are about the US market
Read the full entry
Not banned
Patanjali: Not banned; no national order against any product

Patanjali Ayurved and Divya Pharmacy: what is on record

Nothing made by Patanjali Ayurved or Divya Pharmacy is banned nationally: on record are the 2024 Uttarakhand suspensions (cancelled by the state, reported), the Supreme Court case closed on 11 Aug 2025, Maharashtra's Jun 2026 advertising seizures, and one failed lab test, Arjuna Kwath.

  • Status: Not banned; no national order against any product
  • Who decided: No national regulator action on record
  • Latest step: 6 Nov 2025: Delhi High Court restrains Patanjali from calling all other chyawanprash 'dhoka' (Dabur India v Patanjali Ayurved)
  • Reference: Uttarakhand order of 15 Apr 2024; IMA v Union of India, W.P.(C) 645/2022; Maharashtra FDA seizures of Jun 2026; Maharashtra FDA NSQ table of 9 Oct 2026
  • What to do: Four different things
Read the full entry
Withdrawn
Rule 170: Omitted 1 Jul 2024; stay 27 Aug 2024; stay vacated and case closed 11 Aug 2025

Rule 170: pre-approval of ayurvedic, siddha and unani advertisements (2024 to 2025)

Rule 170, which required state approval of ayurvedic, siddha and unani advertisements, was omitted on 1 Jul 2024; the Supreme Court stayed the omission on 27 Aug 2024 and, on 11 Aug 2025, vacated the stay and disposed of the petition, leaving parties free to challenge the omission separately.

  • Status: Omitted 1 Jul 2024; stay 27 Aug 2024; stay vacated and case closed 11 Aug 2025
  • Who decided: Supreme Court of India
  • Latest step: 11 Aug 2025: Supreme Court vacates the stay and disposes of the IMA petition
  • Reference: Drugs (Fourth Amendment) Rules 2024; Indian Medical Association v Union of India, W.P.(C) 645/2022, order of 11 Aug 2025
  • What to do: Advertising law still applies
Read the full entry
Withdrawn
Patanjali 14 products suspended: Suspended 15 Apr 2024; suspension cancelled by the state 1 Jul 2024 (reported)

Uttarakhand suspended licences of 14 Patanjali and Divya Pharmacy products (Apr 2024)

On 15 Apr 2024 the Uttarakhand State Licensing Authority suspended the manufacturing licences of 14 Divya Pharmacy and Patanjali Ayurved products for repeated misleading advertising; the state cancelled that order on 1 Jul 2024 (reported), and no later order is on public record.

  • Status: Suspended 15 Apr 2024; suspension cancelled by the state 1 Jul 2024 (reported)
  • Who decided: Uttarakhand State Licensing Authority (Ayurveda and Unani)
  • Latest step: 11 Aug 2025: Supreme Court disposes of the IMA petition
  • Reference: Order of 15 Apr 2024 under Rule 159(1), Drugs and Cosmetics Rules; Supreme Court hearing of 30 Jul 2024, Indian Medical Association v Union of India, W.P.(C) 645/2022
  • What to do: A suspension, not a ban
Read the full entry
Not banned
Baidyanath: Not banned in India; on a US FDA import alert since 1 Apr 2021

Baidyanath: what is on record

Baidyanath is not banned in India and no Indian action is on record; the US FDA has listed Shree Baidyanath Ayurved Bhawan (two entities) for bati products, citing lead and mercury, on its heavy-metals import alert since 1 Apr 2021, a US border matter.

  • Status: Not banned in India; on a US FDA import alert since 1 Apr 2021
  • Who decided: US Food and Drug Administration (not an Indian regulator); no Indian action on record
  • Latest step: 1 Apr 2021: US FDA lists Shree Baidyanath Ayurved Bhawan (two entities) and Allayurveda.com, bati products, for lead and mercury on Import Alert 99-42
  • Reference: US FDA Import Alert 99-42 (updated 22 Sep 2026), entry listed 1 Apr 2021
  • What to do: A US entry for named products
Read the full entry
Show as a table
Brand / productActionAuthorityAs ofType
Ayurvedic medicines NSQAyurvedic medicines that failed state lab tests: Maharashtra FDA tableDeclared not of standard quality: Maharashtra FDA table (as of 9 Oct 2026)Maharashtra Food and Drug Administration10 Oct 2026product
Ayurvedic medicine with allopathic drugAyurvedic-labelled products found to contain allopathic drugs: Maharashtra FDA rowsFound to contain undeclared drugs: Maharashtra FDA NSQ table (as of 9 Oct 2026)Maharashtra Food and Drug Administration10 Oct 2026product
Ayush SurakshaAyush Suraksha portal: how to report a misleading ayurvedic advertisementReporting portal live since 30 May 2025Ministry of AYUSH: PvPI-ASU&H, National Pharmacovigilance Coordination Centre at AIIA10 Oct 2026Notice / order
BaidyanathBaidyanath: what is on recordNot banned in India; on a US FDA import alert since 1 Apr 2021US Food and Drug Administration (not an Indian regulator); no Indian action on record10 Oct 2026brand
DaburDabur's ayurvedic products: what is on recordNot banned; no Indian AYUSH action on recordNo Indian regulator action on record10 Oct 2026brand
Phenolphthalein homoeopathicDCGI circular on homoeopathic medicines containing phenolphthalein (Jul 2026)DCGI circular: stop manufacture and sale (6 Jul 2026)Drugs Controller General of India (CDSCO)10 Oct 2026Notice / order
Himalaya WellnessHimalaya Wellness (Liv.52): what is on recordNot banned; no action on recordNo regulator action on record10 Oct 2026brand
Kerala ayurvedic medicines bannedKerala bans sale of six substandard ayurvedic and siddha batches (Jul 2026)Sale banned in Kerala, 6 batches (Jul 2026)Deputy Drugs Controller (Ayurveda), Kerala10 Oct 2026Notice / order
Inducare PharmaMaharashtra FDA cancels Inducare Pharma's licence (Aug 2026)Licence cancelled (8 Aug 2026)Maharashtra Food and Drug Administration10 Oct 2026Notice / order
Divya Pharmacy seizure MaharashtraMaharashtra FDA seizes Divya Pharmacy products over cure claims (Jun 2026)DMR Act seizure; before the Bombay High Court (Jun 2026)Maharashtra Food and Drug Administration10 Oct 2026Notice / order
Maharashtra FDA ayurvedic driveMaharashtra FDA's ayurvedic manufacturers drive: 434 units, 10 licences cancelled (Aug 2026)434 units inspected, 135 notices, 10 licences cancelled (Aug 2026)Maharashtra Food and Drug Administration10 Oct 2026Notice / order
PatanjaliPatanjali Ayurved and Divya Pharmacy: what is on recordNot banned; no national order against any productNo national regulator action on record10 Oct 2026brand
Rule 170Rule 170: pre-approval of ayurvedic, siddha and unani advertisements (2024 to 2025)Omitted 1 Jul 2024; stay 27 Aug 2024; stay vacated and case closed 11 Aug 2025Supreme Court of India10 Oct 2026Notice / order
US FDA import alert ayurvedicUS FDA import alerts and warnings on Indian ayurvedic products (2021 to 2026)US border alerts; not an Indian action (2021 to 2026)US Food and Drug Administration (not an Indian regulator)10 Oct 2026Notice / order
Patanjali 14 products suspendedUttarakhand suspended licences of 14 Patanjali and Divya Pharmacy products (Apr 2024)Suspended 15 Apr 2024; suspension cancelled by the state 1 Jul 2024 (reported)Uttarakhand State Licensing Authority (Ayurveda and Unani)10 Oct 2026Notice / order